Affinage

BTF3

Butyrophilin subfamily 3 member A3 · UniProt O00478

Length
584 aa
Mass
65.0 kDa
Annotated
2026-06-09
37 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

BTF3 is a basal transcription-associated factor that forms a stable complex with RNA polymerase II and functions as a transcriptional co-regulator, with two alternatively spliced isoforms—the active BTF3a and the truncated, RNA pol II-binding but transcriptionally inactive BTF3b lacking the N-terminal 44 residues (PMID:2320128, PMID:1386332). Its co-regulatory role is conserved: the yeast homologs Egd1p/Btt1p stabilize activator–DNA complexes yet redundantly restrain RNA pol II-transcribed gene output, while BTF3a is a CK2 substrate recognized through the CK2 β subunit (PMID:1448098, PMID:8052529, PMID:10094400). BTF3 is essential for early postimplantation mouse development, with homozygous disruption causing embryonic lethality around E6.5 (PMID:7655515). Across cancers BTF3 acts as an oncogenic transcriptional driver, directly or indirectly upregulating targets that span proliferation, metabolism, and stemness programs: BTF3b activates RFC subunit genes to sustain DNA replication and damage repair (PMID:33414468), and BTF3 transcriptionally activates CHD1L, ESR1/ERα, FOXM1 (driving GLUT1-dependent glycolysis), and the autophagy regulator RRAGD upon recruitment by the lncRNA LINC00622 to activate mTORC1 (PMID:33644029, PMID:30315845, PMID:37382415, PMID:40651979). BTF3 also operates post-transcriptionally by stabilizing BMI1 protein to maintain cancer stem-like self-renewal and EMT, with BMI1 loss de-repressing IRF7 and Type I interferon signaling (PMID:31138311, PMID:33383560, PMID:34293363). In addition, BTF3 forms a complex with STAT3 and enhances its phosphorylation and downstream signaling (PMID:38224186). Beyond oncogenesis, BTF3a is induced by Mycobacterium tuberculosis in macrophages where it suppresses autophagic clearance of the pathogen (PMID:30684544).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1990 High

    Established BTF3 as a polypeptide that stably associates with RNA polymerase II and exists as two isoforms differing in transcriptional competence, defining its identity as a basal transcription-associated factor.

    Evidence Protein purification, cDNA cloning and in vitro complex formation assay defining BTF3a (active) versus BTF3b (inactive, pol II-binding)

    PMID:2320128

    Open questions at the time
    • Did not resolve the structural basis by which the N-terminal 44 residues confer transcriptional activity
    • Did not map the contact surface with RNA pol II
  2. 1992 Medium

    Demonstrated that the two isoforms arise by alternative splicing from a single seven-exon gene, explaining the molecular origin of BTF3a/BTF3b.

    Evidence Genomic cloning and sequence analysis of the BTF3 locus

    PMID:1386332

    Open questions at the time
    • Did not establish how splicing between isoforms is regulated
    • Promoter element function only inferred from sequence
  3. 1992 High

    Showed via the yeast ortholog that BTF3-family proteins act as co-activators stabilizing transcription factor–DNA complexes, providing a conserved mechanistic role.

    Evidence Footprinting, gel retardation, purification and EGD1 gene disruption in yeast

    PMID:1448098

    Open questions at the time
    • Whether human BTF3 stabilizes specific activator–DNA complexes was not directly tested
    • Direct DNA-binding contribution of BTF3 itself unresolved
  4. 1994 Medium

    Refined the co-regulator picture by showing the redundant yeast homologs negatively regulate RNA pol II transcription specifically, distinguishing pol II from pol I/III targets.

    Evidence Double gene disruption (Egd1p/Btt1p) with mRNA expression profiling in yeast

    PMID:8052529

    Open questions at the time
    • Activator versus repressor balance in human cells not addressed
    • Mechanism of negative regulation not defined
  5. 1995 High

    Established BTF3 as essential for mammalian development, demonstrating a non-redundant in vivo requirement.

    Evidence Gene-trap insertional knockout in mice with embryo analysis showing E6.5 lethality

    PMID:7655515

    Open questions at the time
    • Cellular cause of lethality not identified
    • Specific developmental transcriptional targets unknown
  6. 1999 Medium

    Identified BTF3a as a CK2 substrate whose phosphorylation requires the CK2 β regulatory subunit, introducing post-translational regulation of BTF3.

    Evidence Yeast two-hybrid, GST pulldown/co-IP and in vitro kinase assays with CK2 holoenzyme and subunits

    PMID:10094400

    Open questions at the time
    • Functional consequence of CK2 phosphorylation on BTF3 activity untested
    • Phosphosite(s) not mapped in vivo
  7. 2007 Medium

    Provided the first cancer-context evidence that BTF3 functions as a transcriptional regulator of cancer-associated genes rather than a direct apoptosis modulator.

    Evidence siRNA knockdown with DNA microarray and apoptosis assays in pancreatic cancer cells

    PMID:17312387

    Open questions at the time
    • Direct versus indirect transcriptional targets not distinguished
    • No promoter-binding evidence
  8. 2018 Medium

    Linked BTF3 to hormone-receptor signaling by showing it regulates ESR1/ERα transcription and modulates drug sensitivity in breast cancer.

    Evidence shRNA knockdown, reporter assays and in vitro/in vivo PI3Kα inhibitor sensitivity in luminal breast cancer

    PMID:30315845

    Open questions at the time
    • Direct binding of BTF3 to the ESR1 promoter not shown
    • Mechanism connecting BTF3 to PI3K pathway indirect
  9. 2019 Medium

    Defined a post-translational oncogenic mechanism: BTF3 stabilizes BMI1 protein to sustain cancer stem-like self-renewal and metastasis.

    Evidence Reciprocal gain/loss-of-function with in vitro and in vivo stemness and tumorigenesis assays in prostate cancer

    PMID:31138311

    Open questions at the time
    • Biochemical basis of BMI1 stabilization not resolved
    • Whether stabilization is direct binding or indirect
  10. 2019 Low

    Implicated STAT3 and stress-kinase signaling as downstream mediators of BTF3 in osteosarcoma.

    Evidence shRNA knockdown with signaling-array profiling and colony formation in Saos-2 cells

    PMID:31205542

    Open questions at the time
    • Signaling-array associations lack mechanistic follow-up
    • Direct versus indirect effects on each kinase undetermined
  11. 2019 Medium

    Extended BTF3 function beyond cancer, showing BTF3a is induced by M. tuberculosis and suppresses autophagic bacterial clearance in macrophages.

    Evidence CRISPR/Cas9 knockdown with autophagy flux, colocalization and CFU assays in THP-1 macrophages

    PMID:30684544

    Open questions at the time
    • Molecular mechanism by which BTF3 restrains autophagy unknown
    • Transcriptional targets in macrophages not identified
  12. 2020 Medium

    Connected BTF3-driven stemness to immune evasion, showing BTF3 loss destabilizes BMI1 and de-represses IRF7/Type I interferon signaling.

    Evidence shRNA knockdown with western blot and reporter analysis in TNBC cells

    PMID:33383560

    Open questions at the time
    • Direct chromatin link from BMI1 to IRF7 not fully resolved here
    • In vivo immune consequences not tested
  13. 2021 Medium

    Assigned isoform-specific function by showing BTF3b activates RFC subunit genes to support DNA replication and damage repair, with RFC3 epistasis confirming the axis.

    Evidence Isoform-specific overexpression/knockdown, reporter, cell cycle, DNA damage and cisplatin sensitivity assays

    PMID:33414468

    Open questions at the time
    • How transcriptionally inactive BTF3b activates RFC genes mechanistically unclear
    • Direct promoter occupancy of RFC genes not detailed
  14. 2021 Medium

    Identified CHD1L as a direct transcriptional target and placed BTF3 within the NAC and a potential HERC2/p53 regulatory axis.

    Evidence RNA-seq + ChIP-seq for targets and IP-MS plus E3 ligase analysis for interactions

    PMID:33644029

    Open questions at the time
    • HERC2/p53 functional consequence not validated
    • NAC interaction not functionally dissected
  15. 2021 Medium

    Confirmed BTF3 acts upstream of BMI1 to control stemness and EMT in a second cancer type, generalizing the BTF3–BMI1 axis.

    Evidence siRNA knockdown with BMI1 rescue, BMI1 inhibitor and stemness/EMT assays in colorectal cancer

    PMID:34293363

    Open questions at the time
    • Whether BTF3 controls BMI1 transcriptionally or post-translationally here not distinguished
    • EMT mechanism downstream of BMI1 not detailed
  16. 2023 Medium

    Demonstrated BTF3 physically interacts with and transcriptionally activates FOXM1 to drive GLUT1-dependent glycolysis, linking BTF3 to tumor metabolism.

    Evidence Co-IP, dual-luciferase reporter, siRNA knockdown with FOXM1 rescue, extracellular flux and xenograft assays in HCC

    PMID:37382415

    Open questions at the time
    • Direct BTF3 occupancy at the FOXM1 promoter versus co-factor role not fully separated
    • Structural basis of BTF3–FOXM1 interaction unknown
  17. 2024 Medium

    Showed BTF3 forms a complex with STAT3 and promotes its phosphorylation to drive NLRP3-dependent pyroptosis, defining a direct BTF3–STAT3 signaling mechanism.

    Evidence Co-IP, ChIP, luciferase, RIP, RNA pull-down and knockdown with flow cytometry in monocytes

    PMID:38224186

    Open questions at the time
    • How BTF3 enhances STAT3 phosphorylation mechanistically unresolved
    • Kinase mediating the effect not identified
  18. 2024 Low

    Proposed PDCD2L as a BTF3 transcriptional target that restrains the p53 pathway to promote HCC proliferation.

    Evidence Knockdown with transcriptional and p53-pathway readouts plus proliferation/apoptosis assays

    PMID:39707202

    Open questions at the time
    • PDCD2L as a direct target not validated by ChIP or reporter
    • Connection to p53 pathway largely correlative
  19. 2025 Medium

    Established lncRNA-guided chromatin recruitment, with LINC00622 directing BTF3 to the RRAGD promoter to activate mTORC1 and suppress autophagic cell death.

    Evidence ChIP, co-IP, reporter and loss-of-function with mTORC1 readout in melanoma models

    PMID:40651979

    Open questions at the time
    • Generality of lncRNA-directed recruitment to other targets unknown
    • Direct BTF3–LINC00622 binding interface not mapped
  20. 2025 Low

    Identified upstream regulation of BTF3 via RPL18-mediated mRNA stabilization feeding STAT3 activation and drug resistance in melanoma.

    Evidence Melanoma cell lines, organoids, xenografts, STAT3 inhibitor treatment and mRNA stability assays

    PMID:41550725

    Open questions at the time
    • mRNA-stabilization mechanism not rigorously resolved biochemically
    • Directness of RPL18–BTF3 mRNA interaction unconfirmed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How BTF3's canonical role as an RNA pol II-associated co-regulator and NAC component mechanistically connects to its diverse oncogenic transcriptional targets and post-translational stabilization of partners remains unresolved.
  • No unifying structural model linking BTF3 chromatin recruitment to specific target selection
  • The biochemical basis distinguishing BTF3a versus BTF3b target specificity is undefined
  • Direct versus cofactor-mediated transcriptional activation not separated across most reported targets

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0003723 RNA binding 2
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1643685 Disease 3 R-HSA-9612973 Autophagy 2
Partners
BMI1CSNK2BFOXM1HERC2STAT3
Complex memberships
BTF3/STAT3 complexRNA polymerase II complexnascent-polypeptide-associated complex (NAC)

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1990 BTF3 forms a stable complex with RNA polymerase II. Two isoforms exist: BTF3a (27 kDa, transcriptionally active) and BTF3b (lacking the first 44 residues of BTF3a, transcriptionally inactive despite retaining RNA pol II binding ability). Protein purification, cDNA cloning, in vitro complex formation assay Nature High 2320128
1992 The BTF3 gene contains seven exons; BTF3a and BTF3b are products of alternative splicing from the same gene. A putative TATA box(es) and CAAT box were identified in the promoter region. Genomic cloning, cDNA library screening, sequence analysis Gene Medium 1386332
1992 Yeast homolog of BTF3 (EGD1/Egd1p) stabilizes the Gal4p transcriptional activator-DNA complex (gel retardation assay); loss of EGD1 reduces galactose-regulated gene induction, placing BTF3 homolog as a co-activator facilitating transcription factor-DNA interaction. Filter binding, footprinting, gel retardation, gene disruption, purification Molecular and cellular biology High 1448098
1994 Yeast BTF3 homologs (Egd1p and Btt1p) have redundant functions; double deletion elevates GAL1, GAL10, ACT1, and SSO1 mRNA levels (RNA pol II transcribed genes) but not rRNA or tRNA, indicating a negative regulatory role on RNA pol II transcription. Gene disruption, mRNA expression analysis Nucleic acids research Medium 8052529
1995 Homozygous disruption of the BTF3 gene in mice causes lethality at embryonic day ~6.5 (early postimplantation), establishing BTF3 as essential for early postimplantation development. Retroviral gene trap insertional mutagenesis, germline transmission, embryo analysis Transgenic research High 7655515
1999 BTF3a is phosphorylated in vitro by the CK2 α2β2 holoenzyme (but not by α or α' alone), and physically interacts with CK2 subunit β both in yeast two-hybrid and GST pulldown/co-immunoprecipitation assays, identifying BTF3a as a CK2 substrate requiring the β subunit for recognition. Yeast two-hybrid, GST pulldown, co-immunoprecipitation, in vitro kinase assay Molecular and cellular biochemistry Medium 10094400
2007 BTF3 silencing in pancreatic cancer cells down-regulates cancer-associated genes (EPHB2, ABL2, HPSE2, ATM) and up-regulates others (KRAG, RRAS2, NF-κB, etc.) without affecting chemotherapy- or radiotherapy-induced apoptosis, supporting a role as a transcriptional regulator rather than direct apoptosis modulator in this context. siRNA knockdown, DNA microarray analysis, cell growth and apoptosis assays Cancer biology & therapy Medium 17312387
2019 BTF3 stabilizes BMI1 protein in prostate cancer cells; BTF3 loss reduces BMI1 levels and impairs cancer stem-like self-renewal and metastatic potential, while BTF3 overexpression promotes these traits. Gain- and loss-of-function (ectopic overexpression and shRNA), in vitro and in vivo tumorigenic/stemness assays, immunofluorescence Journal of experimental & clinical cancer research Medium 31138311
2020 BTF3 knockdown in TNBC cells increases BMI1 protein degradation, leading to de-repression of IRF7 transcription and activation of the Type I interferon signaling pathway, linking BTF3-mediated stemness to immune evasion. shRNA knockdown, bioinformatics, western blot, transcriptional reporter analysis Biochemical and biophysical research communications Medium 33383560
2021 BTF3b (but not BTF3a) transcriptionally upregulates RFC (Replication Factor C) family subunit genes involved in DNA replication and damage repair; BTF3 knockdown reduces RFC expression, attenuates DNA replication, impairs DNA damage repair, and increases G2/M arrest. RFC3 knockdown diminishes the growth advantage conferred by BTF3b overexpression. Isoform-specific overexpression/knockdown, reporter assay, cell cycle analysis, DNA damage assay, in vitro and in vivo cisplatin sensitivity Cell death & disease Medium 33414468
2021 BTF3 transcriptionally targets CHD1L (identified by RNA-seq + ChIP-seq); BTF3 also interacts with proteins in the nascent-polypeptide-associated complex (NAC) and may inhibit E3 ubiquitin ligase HERC2-mediated p53 degradation (identified by IP-MS and E3 ligase analysis). RNA-seq, ChIP-seq, immunoprecipitation-mass spectrometry, E3 ubiquitin ligase analysis Frontiers in cell and developmental biology Medium 33644029
2021 BTF3 regulates BMI1 expression in colorectal cancer; BMI1 overexpression partially rescues stem cell-like traits and EMT after BTF3 knockdown, placing BTF3 upstream of BMI1 in control of CRC stemness and epithelial-mesenchymal transition. siRNA knockdown, rescue overexpression, BMI1 inhibitor (PTC-209) treatment, stemness assays (CD133, colony formation, tumorosphere), EMT marker expression International journal of biological macromolecules Medium 34293363
2018 BTF3 regulates ESR1 (ERα) transcriptional expression in luminal breast cancer cells; BTF3 knockdown reduces ERα-dependent transcription and sensitizes ER+ cells to PI3Kα inhibitor BYL-719 both in vitro and in vivo. shRNA knockdown, transcriptional reporter assay, gene expression analysis, in vitro and in vivo drug sensitivity assays Cancer letters Medium 30315845
2023 BTF3 directly interacts with FOXM1 in HCC cells (co-immunoprecipitation) and transcriptionally activates FOXM1; BTF3 knockdown reduces FOXM1 and GLUT1 expression, attenuating glycolysis (ECAR, glucose consumption, lactate production). FOXM1 overexpression rescues glycolytic activity in BTF3-knockdown cells. Co-immunoprecipitation, dual-luciferase reporter assay, siRNA knockdown, FOXM1 rescue overexpression, XF96 extracellular flux analysis, xenograft model Cancer biology & therapy Medium 37382415
2024 BTF3 forms a complex with STAT3 in monocytes (co-immunoprecipitation); this BTF3/STAT3 complex promotes STAT3 phosphorylation, which activates NLRP3 promoter-driven pyroptosis and apoptosis. BTF3 depletion inhibits STAT3 phosphorylation and suppresses pyroptosis. Co-immunoprecipitation, chromatin immunoprecipitation, luciferase reporter, RNA immunoprecipitation, RNA pull-down, CRISPR/siRNA knockdown, flow cytometry Clinical and translational medicine Medium 38224186
2019 BTF3a knockdown (CRISPR/Cas9) in THP-1-derived macrophages increases autophagy flux and lysosomal targeting of Mycobacterium tuberculosis-containing autophagosomes, resulting in enhanced intracellular Mtb clearance. Mtb infection upregulates BTF3a expression in macrophages. CRISPR/Cas9 knockdown, LC3B-II turnover assay, LAMP1 expression, confocal microscopy (LC3B/lysotracker/Rab7 colocalization), CFU assay Life sciences Medium 30684544
2024 BTF3 transcriptionally upregulates PDCD2L in hepatocellular carcinoma; PDCD2L in turn restrains the p53 pathway to promote proliferation and inhibit apoptosis. BTF3 knockdown inhibits proliferation and promotes apoptosis in HCC cells. Knockdown experiments, transcriptional analysis, cell function assays (proliferation, apoptosis), p53 pathway readout Molecular medicine Low 39707202
2025 BTF3 is recruited by LINC00622 lncRNA to the RRAGD promoter to transcriptionally enhance RRAGD expression, activating mTORC1 and suppressing autophagic cell death in cutaneous melanoma. ChIP, co-immunoprecipitation, reporter assays, loss-of-function knockdown, in vitro and in vivo tumor models Cell death & disease Medium 40651979
2025 RPL18 stabilizes BTF3 mRNA, increasing BTF3 protein levels and downstream STAT3 activation, promoting melanoma proliferation, migration, and temozolomide resistance. Pharmacologic STAT3 inhibition reverses RPL18-dependent oncogenic phenotypes. Melanoma cell lines, patient-derived organoids, xenograft models, STAT3 inhibitor treatment, mRNA stability assay (implied), western blot iScience Low 41550725
2019 BTF3 knockdown in osteosarcoma (Saos-2) cells activates STAT3, S6 ribosomal protein, HSP27, and SAPK/JNK2 (all inhibited by BTF3 silencing), while SAPK/JNK1 is upregulated, identifying these as signaling mediators downstream of BTF3. Lentivirus shRNA knockdown, PathScan Intracellular Signaling Array, flow cytometry, colony formation assay Journal of Cancer Low 31205542

Source papers

Stage 0 corpus · 37 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1990 Sequencing and expression of complementary DNA for the general transcription factor BTF3. Nature 106 2320128
1995 An insertional mutation in the BTF3 transcription factor gene leads to an early postimplantation lethality in mice. Transgenic research 88 7655515
2007 Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells. Cancer biology & therapy 52 17312387
2013 Quantitative analysis of BTF3, HINT1, NDRG1 and ODC1 protein over-expression in human prostate cancer tissue. PloS one 44 24386364
1992 The EGD1 product, a yeast homolog of human BTF3, may be involved in GAL4 DNA binding. Molecular and cellular biology 43 1448098
2005 Translation initiation factor (iso) 4E interacts with BTF3, the beta subunit of the nascent polypeptide-associated complex. Gene 42 15716105
1994 Yeast BTF3 protein is encoded by duplicated genes and inhibits the expression of some genes in vivo. Nucleic acids research 41 8052529
2023 Matrine Targets BTF3 to Inhibit the Growth of Canine Mammary Tumor Cells. International journal of molecular sciences 37 38203709
2019 BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1. Journal of experimental & clinical cancer research : CR 34 31138311
1992 Genomic structure of the putative BTF3 transcription factor. Gene 31 1386332
2018 Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα. Cancer letters 26 30315845
2013 Clinicopathological significance of BTF3 expression in colorectal cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 23 23532689
2021 BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell death & disease 21 33414468
2021 BTF3-mediated regulation of BMI1 promotes colorectal cancer through influencing epithelial-mesenchymal transition and stem cell-like traits. International journal of biological macromolecules 21 34293363
2016 Kahweol induces apoptosis by suppressing BTF3 expression through the ERK signaling pathway in non-small cell lung cancer cells. International journal of oncology 21 27748804
2021 MiR-27a-5p regulates acrylamide-induced mitochondrial dysfunction and intrinsic apoptosis via targeting Btf3 in rats. Food chemistry 20 34416489
2023 BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1. Cancer biology & therapy 16 37382415
1999 BTF3 is a potential new substrate of protein kinase CK2. Molecular and cellular biochemistry 16 10094400
2021 Enhanced Room-Temperature Ionic Conductivity of NaCB11H12 via High-Energy Mechanical Milling. ACS applied materials & interfaces 12 34927409
2022 LncRNA-ZNF252P-AS1/miR-15b-5p promotes the proliferation of keloid fibroblast by regulating the BTF3-STAT3 signaling pathway. Journal of dermatological science 11 36641250
2020 miR‑802 inhibits the epithelial‑mesenchymal transition, migration and invasion of cervical cancer by regulating BTF3. Molecular medicine reports 11 32582971
2019 Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 10 31404775
2020 BTF3 promotes stemness and inhibits TypeⅠInterferon signaling pathway in triple-negative breast cancer. Biochemical and biophysical research communications 9 33383560
2019 BTF3 Silencing Inhibits the Proliferation of Osteosarcoma Cells. Journal of Cancer 9 31205542
2024 ARID5B-mediated LINC01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the BTF3/STAT3 complex in β2GPI/anti-β2GPI-treated monocytes. Clinical and translational medicine 8 38224186
2021 Molecular Characterization of the Oncogene BTF3 and Its Targets in Colorectal Cancer. Frontiers in cell and developmental biology 8 33644029
1997 The visual assignment of genes by fiber-fish: BTF3 protein homologue gene (BTF3) and a novel pseudogene of human RNA helicase A (DDX9P) on 13q22. Genomics 8 9325059
2017 Transgenic tobacco plants constitutively expressing peanut BTF3 exhibit increased growth and tolerance to abiotic stresses. Plant biology (Stuttgart, Germany) 7 27981726
2012 Human beta casein fragment (54-59) modulates M. bovis BCG survival and basic transcription factor 3 (BTF3) expression in THP-1 cell line. PloS one 7 23029305
2019 Targeted depletion of BTF3a in macrophages activates autophagic pathway to eliminate Mycobacterium tuberculosis. Life sciences 5 30684544
1996 BTF3 is evolutionarily conserved in fission yeast. Biochimica et biophysica acta 5 8809106
2024 METTL3-driven m6A modification of lncRNA FAM230B suppresses ferroptosis by modulating miR-27a-5p/BTF3 axis in gastric cancer. Biochimica et biophysica acta. General subjects 4 39278369
2024 BTF3 affects hepatocellular carcinoma progression by transcriptionally upregulating PDCD2L and inactivating p53 signaling. Molecular medicine (Cambridge, Mass.) 2 39707202
2025 Comparative transcriptomics of transgenic tobacco plants overexpressing Miscanthus sinensis BTF3. BMC genomics 1 40389874
2025 LINC00622 transcriptionally promotes RRAGD to repress mTORC1-modulated autophagic cell death by associating with BTF3 in cutaneous melanoma. Cell death & disease 1 40651979
2026 IGLC3- tumor cells drive chemoresistance in colorectal cancer by polarizing SPP1+ macrophages via the CD44-Wnt-BTF3 axis. Frontiers in immunology 0 41993204
2025 RPL18 promotes melanoma progression and drug resistance via BTF3/STAT3-dependent mechanisms and immune modulation. iScience 0 41550725

Missed literature

Know a paper Affinage missed for BTF3? Flag it for the maintainers and the community.

No submissions yet.